Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide - approved to treat Type 2 Diabetes ("T2D") under the brand name ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...

Recent research found that people taking semaglutide—the active ingredient in Ozempic and Wegovy—had more hair loss than people on other weight loss drugs. The rapid weight loss caused by ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

We all know that Ozempic, a GLP-1 receptor agonist medication, also called semaglutide, causes weight loss. On average, high-dose semaglutides, like in Wegovy, cause people to lose somewhere ...